Handelsavisen
prelaunch
Companies Healthcare 6794.TW
67
6794.TW TWSE Biotechnology & Medical Research

Unicocell Biomed Co Ltd

$79,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-432,8 %
ROE
-13,3 %
Net margin
-381,5 %
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Unicocell Biomed Co Ltd is a biotechnology and medical research company that operates in the pharmaceuticals and medical research sector, primarily generating revenue through the development and commercialization of biomed-related products and services.

Business. Unicocell Biomed Co Ltd (6794.TW) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-13,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6794.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6794.TW. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Unicocell Biomed Co Ltd (6794.TW) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Unicocell Biomed Co Ltd maintains a strong liquidity position with a current ratio of 37.98, indicating that its current assets significantly exceed its current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The company's debt-to-equity ratio is 0.07, suggesting a relatively low reliance on debt financing compared to equity.

    The company's profitability is currently negative, with a return on equity of -13.27% and a return on assets of -12.14%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of TWD 130,278,000 and net loss of TWD 114,836,000 further underscore the company's financial challenges.

    Unicocell Biomed Co Ltd's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if its primary market or product line experiences a downturn.

    The company's growth trajectory is currently negative, with a significant operating and net loss. The operating cash flow of TWD -91,310,000 and free cash flow of TWD -100,013,000 indicate that the company is not generating sufficient cash from operations to sustain its activities or fund growth initiatives. The capital expenditure of TWD -5,727,000 suggests minimal investment in long-term assets, which may limit future growth potential.

    The company faces medium liquidity risk due to its negative net cash position after subtracting total debt. While the dilution risk is currently low, the company's financial performance and cash flow challenges may necessitate future equity or debt financing, which could lead to dilution. The risk assessment highlights the need for the company to improve its cash flow generation and reduce its operating losses to maintain financial stability.

    Recent financial filings and transcripts indicate that the company is actively managing its financial position, but the negative operating and net income suggest ongoing challenges in achieving profitability. The company's management has not disclosed specific strategies to address these issues in the available documents.

    Key takeaways
    • Unicocell Biomed Co Ltd has a strong liquidity position as indicated by its high current ratio, but its negative net cash position after subtracting total debt raises concerns.
    • The company is currently unprofitable, with significant operating and net losses, and negative returns on equity and assets.
    • Revenue is concentrated in a single segment, and there is no geographic diversification provided in the available data.
    • The company's growth trajectory is negative, with substantial operating and free cash flow deficits.
    • The company faces medium liquidity risk and low dilution risk, but its financial performance may necessitate future financing that could lead to dilution.
    • "margin_outlook_rationale": "The company's margin outlook is negative due to its significant operating and net losses, which indicate declining profitability.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $79,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $865.4M
    Net cash
    -$32.0M
    Current ratio
    38.0
    Debt / equity
    0.1
    ROA
    -12.1%
    ROE
    -13.3%
    Cash conversion
    80.0%
    CapEx / revenue
    -19.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-432,8 %Below median
    Net Margin-381,5 %Below median
    ROE-13,3 %Above median
    Capex / Rev-19,0 %Below median
    D/E0,07Below median
    Cash Conv0,80Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Unicocell Biomed Co Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6794.TWCanonical
    TWSE · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage